微芯生物定增被问询，要求说明销售业务合规性

Core Viewpoint - Shenzhen Micron Biotechnology Co., Ltd. plans to issue shares to raise up to 950 million yuan for innovative drug research and development, a new drug manufacturing base, and to supplement working capital, with the Shanghai Stock Exchange issuing an inquiry letter for review [2] Group 1 - The company reported a continuous increase in sales expenses during the reporting period, primarily due to the commercialization of its innovative drug, Siglitazone Sodium, which was approved for market in October 2021 [2] - The increase in sales expenses is attributed to the company's efforts to enhance market recognition and coverage of Siglitazone Sodium through increased marketing activities [2] - Sales expenses mainly consist of employee compensation and marketing promotion costs, with the company implementing internal control systems to regulate marketing activities [2] Group 2 - Micron Biotechnology utilizes both its own sales team and commissioned promotion service providers for marketing activities, focusing on the experience of the service providers' teams [3] - The main promotion service providers are independent and not related to the company, with service fees paid through public bank transactions as per contractual agreements [3] - The company ensures that there are no payments made to related parties, employees, or other stakeholders in its marketing service arrangements [3]